The SR-B1 Receptor As a Potential Target for Treating Glioblastoma

Overview

Journal J Oncol

Specialty Oncology

Date 2019 Jul 6

PMID 31275377

Citations 13

Authors

Ethan Berney

Nirupama Sabnis

Marlyn Panchoo

Sangram Raut

Rob Dickerman

Andras G Lacko

Affiliations

Soon will be listed here.

Abstract

Purpose: The goal of these studies was to provide proof of concept for a novel targeted therapy for . These studies involve the evaluation of reconstituted high density lipoprotein (rHDL) nanoparticles (NPs) as delivery agents for the drug, mammalian Target of Rapamycin (mTOR) inhibitor Everolimus (EVR) to GBM cells. Cytotoxicity studies and assessment of downstream effects, including apoptosis, migration, and cell cycle events, were probed, in relation to the expression of scavenger receptor B type 1 (SR-B1) by GBM cells.

Results: Findings from cytotoxicity studies indicate that the rHDL/EVR formulation was 185 times more potent than free EVR against high SR-B1 expressing cell line (LN 229). Cell cycle analysis revealed that rHDL/EVR treated LN229 cells had a 5.8 times higher apoptotic cell population than those treated with EVR. The sensitivity of GBM cells to EVR treatment was strongly correlated with SR-B1 expression.

Conclusions: These studies present strong proof of concept regarding the efficacy of delivering EVR and likely other agents, via a biocompatible transport system, targeted to the SR-B1 receptor that is upregulated in most cancers, including GBM. Targeting the SR-B1 receptor could thus lead to effective personalized therapy of GBM.

Citing Articles

Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.

Wang Y, Liu C, Fang C, Peng Q, Qin W, Yan X Nanomicro Lett. 2024; 17(1):30.

PMID: 39347944 PMC: 11442722. DOI: 10.1007/s40820-024-01533-y.

Photophysical Characterization and In Vitro Evaluation of α-Mangostin-Loaded HDL Mimetic Nano-Complex in LN-229 Glioblastoma Spheroid Model.

Kapic A, Sabnis N, Dossou A, Chavez J, Ceresa L, Gryczynski Z Int J Mol Sci. 2024; 25(13).

PMID: 39000485 PMC: 11242846. DOI: 10.3390/ijms25137378.

Biomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme.

Lim X, Capinpin S, Bolem N, Foo A, Yip W, Kumar A Bioeng Transl Med. 2023; 8(3):e10483.

PMID: 37206213 PMC: 10189489. DOI: 10.1002/btm2.10483.

Ganglioside GM3-Functionalized Reconstituted High-Density Lipoprotein (GM3-rHDL) as a Novel Nanocarrier Enhances Antiatherosclerotic Efficacy of Statins in apoE C57BL/6 Mice.

Wei B, Li Y, Ao M, Shao W, Wang K, Rong T Pharmaceutics. 2022; 14(11).

PMID: 36432725 PMC: 9698139. DOI: 10.3390/pharmaceutics14112534.

Everolimus-Loaded Reconstituted High-Density Lipoprotein Prepared by a Novel Dual Centrifugation Approach for Anti-Atherosclerotic Therapy.

Deuringer B, Hardtner C, Krebs K, Thomann R, Holzer M, Hilgendorf I Int J Nanomedicine. 2022; 17:5081-5097.

PMID: 36340183 PMC: 9635393. DOI: 10.2147/IJN.S381483.

References

Goti D, Hrzenjak A, Levak-Frank S, Frank S, van der Westhuyzen D, Malle E . Scavenger receptor class B, type I is expressed in porcine brain capillary endothelial cells and contributes to selective uptake of HDL-associated vitamin E. J Neurochem. 2001; 76(2):498-508. DOI: 10.1046/j.1471-4159.2001.00100.x. View

Husemann J, Silverstein S . Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. Am J Pathol. 2001; 158(3):825-32. PMC: 1850374. DOI: 10.1016/S0002-9440(10)64030-8. View

Lacko A, Nair M, Paranjape S, Johnso S, McConathy W . High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002; 22(4):2045-9. View

Rigotti A, Miettinen H, Krieger M . The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev. 2003; 24(3):357-87. DOI: 10.1210/er.2001-0037. View

Lacko A, Nair M, Paranjape S, Mooberry L, McConathy W . Trojan horse meets magic bullet to spawn a novel, highly effective drug delivery model. Chemotherapy. 2006; 52(4):171-3. DOI: 10.1159/000093268. View

Kratzer I, Wernig K, Panzenboeck U, Bernhart E, Reicher H, Wronski R . Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release. 2007; 117(3):301-11. PMC: 4861216. DOI: 10.1016/j.jconrel.2006.11.020. View

Lacko A, Nair M, Prokai L, McConathy W . Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv. 2007; 4(6):665-75. DOI: 10.1517/17425247.4.6.665. View

McConathy W, Nair M, Paranjape S, Mooberry L, Lacko A . Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs. 2008; 19(2):183-8. DOI: 10.1097/CAD.0b013e3282f1da86. View

Mooberry L, Nair M, Paranjape S, McConathy W, Lacko A . Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2009; 18(1):53-8. DOI: 10.3109/10611860903156419. View

10.

Shahzad M, Mangala L, Han H, Lu C, Bottsford-Miller J, Nishimura M . Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia. 2011; 13(4):309-19. PMC: 3071079. DOI: 10.1593/neo.101372. View

11.

Yang M, Chen J, Cao W, Ding L, Ng K, Jin H . Attenuation of nontargeted cell-kill using a high-density lipoprotein-mimicking peptide--phospholipid nanoscaffold. Nanomedicine (Lond). 2011; 6(4):631-41. DOI: 10.2217/nnm.11.10. View

12.

Sabnis N, Nair M, Israel M, McConathy W, Lacko A . Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine. 2012; 7:975-83. PMC: 3289451. DOI: 10.2147/IJN.S28029. View

13.

Fioravanti J, Medina-Echeverz J, Ardaiz N, Gomar C, Parra-Guillen Z, Prieto J . The fusion protein of IFN-α and apolipoprotein A-I crosses the blood-brain barrier by a saturable transport mechanism. J Immunol. 2012; 188(8):3988-92. DOI: 10.4049/jimmunol.1101598. View

14.

Yang S, Damiano M, Zhang H, Tripathy S, Luthi A, Rink J . Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci U S A. 2013; 110(7):2511-6. PMC: 3574906. DOI: 10.1073/pnas.1213657110. View

15.

Olar A, Aldape K . Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol. 2013; 232(2):165-77. PMC: 4138801. DOI: 10.1002/path.4282. View

16.

Omuro A, DeAngelis L . Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17):1842-50. DOI: 10.1001/jama.2013.280319. View

17.

Rosenberg S . Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Ther. 2014; 21(2):45-7. PMC: 6354240. DOI: 10.1038/cgt.2014.3. View

18.

Larson E, Peterson H, Lamoreaux W, Mackay A, Fairbanks R, Call J . Clinical outcomes following salvage Gamma Knife radiosurgery for recurrent glioblastoma. World J Clin Oncol. 2014; 5(2):142-8. PMC: 4014786. DOI: 10.5306/wjco.v5.i2.142. View

19.

Huang H, Cruz W, Chen J, Zheng G . Learning from biology: synthetic lipoproteins for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014; 7(3):298-314. PMC: 4397116. DOI: 10.1002/wnan.1308. View

20.

Ma D, Galanis E, Anderson S, Schiff D, Kaufmann T, Peller P . A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 2014; 17(9):1261-9. PMC: 4588750. DOI: 10.1093/neuonc/nou328. View